STOCK TITAN

Standard BioTools (LAB) DEF 14A Filings

LAB NASDAQ

Here are the DEF 14A proxy statements from Standard BioTools Inc. (LAB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow LAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LAB filings page.

Rhea-AI Summary

Standard BioTools Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 17, 2026 at 11:30 a.m. Eastern Time. Proposals include electing three Class I directors, an advisory say‑on‑pay vote, ratifying PwC as auditor, approving a new 2026 Equity Incentive Plan, and adding 1,200,000 shares to the 2017 Employee Stock Purchase Plan.

The proxy highlights a 2025 divestiture of SomaLogic and related units to Illumina for up to $425 million plus 10 years of royalties, with continuing-operations revenue of $85.3 million and $210.7 million in cash and investments as of December 31, 2025, rising to about $550 million after the deal closing in January 2026. It also describes board structure, governance practices, risk oversight, executive compensation philosophy, and strong 2025 say‑on‑pay support of approximately 98.29%.